GTGordana Tasic

Gordana Tasic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gordana Tasic has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative in silico/in vitro analysis of pharmacokinetic profiles of bet inhibitors

    by Mladen Koravovic, Milena Kovacevic, Marija Jovanovic, Gordana Tasic, Anand Mayasundari, Gisele Nishiguchi, Bojan Markovic, Zoran Rankovic, Vladimir Savic

    Pharmacokinetic limitations are a common cause of drug development failure, making early-stage profiling essential to mitigate financial risks and guide compound optimization. The computational tools capable of predicting pharmacokinetic properties offer a valuable resource for the prioritizing of candidates during early discovery phases. This study provides a comparative analysis of in silico and in vitro pharmacokinetic profiles of bromodomain and extraterminal domain (BET) inhibitors (BIs), focusing on sixteen (+)-JQ1- -derived compounds we previously synthesized. Using ADMETlab 2.0 software, we predicted key absorption, distribution, metabolism, and excretion (ADME) parameters and compared them with experimentally determined data. Strong correlations were observed for plasma protein binding, whereas notable dis-crepancies were identified in permeability and clearance values. Additionally, the analysis underscores the role of CYP3A4 as a critical enzyme in the meta-bolism of several BIs. These findings demonstrate the utility of computational tools like ADMETlab 2.0 for early pharmacokinetic profiling while highlighting the need for validation and refinement of predictive models. This work provides valuable insights into the pharmacokinetics of BIs and supports the integration of computational and experimental approaches in drug discovery.


  • Synthesis of hydantoins from N‐Boc protected amino acid derived amides using polymer‐supported PPh3/CBr4 as a reagent

    by Gordana Tasic, Nikola Mitrovic, Milena Simic, Mladen Koravovic, Predrag Jovanovic, Milos Petkovic, Milos Jovanovic, Branka Ivkovic, Vladimir Savic


  • Open Access

    Synthesis and in vitro study of redox properties of pyrrole and halogenated pyrrole derivatives

    by Miloš R. Petković, Jelena M. Kotur-Stevuljević, Predrag M. Jovanović, Miloš D. Jovanović, Nikola M. Mitrović, Milena R. Simić, Gordana D. Tasić, Vladimir M. Savić

    The redox balance plays a crucial role in maintaining biological processes under normal conditions. Antioxidants inhibit and reduce harmful oxidation processes, while pro-oxidants can act as anti-cancer agents by promoting ROS-mediated cell death. The aim of this study is to compare the redox properties of seven newly synthesised tribromopyrrole derivatives with three novel and four previously synthesized non-halogenated analogues in an in vitro model (in human serum) and with exogenously induced oxidative stress. The obtained values of their oxy scores (OS) were compared and the result showed that four non-halogenated pyrrole derivatives with secondary amide group M2, M10, M11 and M12 have lower OS values than Trolox, a water-soluble analogue of vitamin E with proven antioxidant properties. All four compounds show strong resistance to oxidative stress, which is reflected in the maintenance of negative OS values when exposed to exogenous oxidative stress using TBH in the reaction mixture. This capability to resist invading ROS should be expected also in an endogenous environment, where constant prooxidant production takes place at a low, homeostatic level, but even more so in pathological conditions. The tribrominated derivative M15 showed prooxidant activity with a significantly higher OS value than all other compounds tested. The comparison of the dose-response of Trolox and the five compounds with the lowest OS also shows that compounds M2, M7 and M10 have better antioxidant activity than Trolox.


  • Open Access

    In vitro study of redox properties of azolyl-lactones in human serum

    by Milena R. Simić, Jelena M. Kotur-Stevuljević, Predrag M. Jovanović, Miloš R. Petković, Miloš D. Jovanović, Gordana D. Tasić, Vladimir M. Savić

    Disruption of the redox balance in the body causes oxidative stress that can initiate many diseases. While antioxidants reduce the level of oxidizing compounds in the medium, prooxidants promote the opposite process and have been used in therapies in particular those of cancer diseases. In this study, a series of azolyl lactones, were tested in human serum as a biological matrix and the obtained values of their oxy scores (OS) were compared. The antioxidative properties of these compounds were also tested under conditions of induced oxidative stress using an external prooxidant, t-butylhydroperoxide. The results showed that the sulphur analogue 4-azolyl coumarin 5 has the best antioxidant properties (OS ?2.2), while the halogenated derivatives of pyrazolylcoumarin 7 and 8 act as prooxidants, but successfully resist oxidative stress (OS 2.7 and 2.0, respectively). Related phthalides and isocoumarins showed prooxidative properties, but azolyl isocoumarins 10 and 11 show the strongest resistance to oxidative stress, reflected in their negative oxy score value (OS ?2.1 and ?1.1, respectively). The results demonstrated that combining two pharmacophores with known redox properties can produce potent compounds in both directions, with the antioxidative and the prooxidative characteristics.


  • Open Access

    Protein degradation induced by PROTAC molecules as an emerging drug discovery strategy

    by Mladen Koravovic, Bojan Markovic, Milena Kovacevic, Milena Rmandic, Gordana Tasic

    The traditional concept of drug discovery is based on the occupancy driven pharmacology model. It implies the development of inhibitors occupying binding sites that directly affect protein functions. Therefore, proteins that do not have such binding sites are generally considered as pharmacologically intractable. Furthermore, drugs that act in this way must be administered in dosage regimens that often result in high systemic drug exposures in order to maintain sufficient protein inhibition. Thus, there is a risk of the onset of off target binding and side effects. The landscape of drug discovery has been markedly changed since proteolysis targeting chimera (PROTAC) molecules emerged twenty years ago as a part of the event-driven pharmacology model. These are bifunctional molecules that harness the ubiquitin-proteasome system, and are composed of a ligand that binds the protein of interest (POI), a ligand that recruits E3 ubiquitin ligase (E3UL) and a linker that connects these two parts. Pharmacologically, PROTACs bring POI and E3UL into close proximity, which triggers the formation of a functional ternary complex POI? ?PROTAC?E3UL. This event drives polyubiquitination and subsequent POI degradation by the 26S proteasome. The development and exceptional properties of PROTAC molecules that brought them to clinical studies will be discussed in this paper.


  • Open Access

    Photocontrollable PROTAC molecules: Structure and mechanism of action

    by Mladen Koravović, Gordana Tasić, Milena Rmandić, Bojan Marković

    Traditional drug discovery strategies are usually focused on occupancy of binding sites that directly affect functions of proteins. Hence, proteins that lack such binding sites are generally considered pharmacologically intractable. Modulators of protein activity, especially inhibitors, must be applied in appropriate dosage regimens that often lead to high systemic drug exposures in order to maintain sufficient protein inhibition in vivo. Consequently, there is a risk of undesirable off-target drug binding and side effects. Recently, PROteolysis TArgeting Chimera (PROTAC) technology has emerged as a new pharmacological modality that exploits PROTAC molecules for induced protein degradation. PROTAC molecule is a heterobifunctional structure consisting of a ligand that binds a protein of interest (POI), a ligand for recruiting an E3 ubiquitin ligase (an enzyme involved in the POI ubiquitination) and a linker that connects these two. After POI-PROTAC-E3 ubiquitin ligase ternary complex formation, the POI undergoes ubiquitination (an enzymatic post-translational modification in which ubiquitin is attached to the POI) and degradation. By merging the principles of photopharmacology and PROTAC technology, photocontrollable PROTACs for spatiotemporal control of induced protein degradation have recently emerged. The main advantage of photocontrollable over conventional PROTACs is the possible prevention of off-target toxicity thanks to local photoactivation.


  • Synthesis of 2-unsubstituted imidazolones from bisamides via a one-pot, domino dehydration/base promoted cyclisation process

    by Dimitrije Djukanovic, Milos Petkovic, Milena Simic, Predrag Jovanovic, Gordana Tasic, Vladimir Savic


  • Preparation of pyrrolizinone derivatives via sequential transformations of cyclic allyl imides: synthesis of quinolactacide and marinamide

    by Milena Simic, Gordana Tasic, Predrag Jovanovic, Milos Petkovic, Vladimir Savic

    A facile synthetic route has been developed for the preparation of pyrrolizinone derivatives employing N-allyl imides as starting materials. The nucleophilic addition of a vinyl Grignard reagent/RCM/elimination sequence afforded pyrrolizinones in good yields and has been applied for the preparation of naturally occurring quinolactacide and marinamide.


  • Open Access

    Synthesis of substituted allyl acetates from heterocyclic dienes by Pd-promoted arylation-acetoxylation cascade

    by Milena Simic, Milos Petkovic, Predrag Jovanovic, Gordana Tasic, Vladimir Savic

    Pd-catalysed arylation?acetoxylation cascade, a previously reported methodology, was applied in the functionalisation of unsymmetrical dienes. Both explored classes of compounds, isoquinoline and ?-carboline-derived dienes, afforded single regioisomers. Although further improvements of the process are necessary, primarily due to lower yields, the described functionalisation of the studied compounds might be useful in the synthesis of emetine and related naturally occurring compounds.


  • Open Access

    Synthesis, cytotoxicity and computational study of novel protoberberine derivatives

    by Milena R. Simić, Ana B. Damjanović, Marko D. Kalinić, Gordana D. Tasić, Slavica M. Erić, Jelena A. Antić-Stanković, Vladimir M. Savić

    A novel and efficient synthetic route has been developed for the preparation of protoberberine derivatives. The methodology designed to control, primarily, substitution patterns on the terminal rings, was used to access a small array of these compounds. Initial biological profiling suggested anticancer potential of synthesised derivatives while structure-based target fishing has identified their potential targets and has established rational basis for further structural modifications. Although the activities need further improvement, our study demonstrated that the described approach may be useful in the discovery of the novel lead compounds.